Phio Pharmaceuticals reports that its Safety Monitoring Committee has completed a positive safety review of Phase 1b skin cancer trial PH-762, showing no serious adverse events and an 85% pathological response rate at the highest dose cohort.
https://finviz.com/quote.ashx?t=PHIO&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.